PSMD2表达对非小细胞肺癌预后及免疫微环境的影响

The Effect of PSMD2 Expression on the Prog-nosis and Immune Microenvironment of Non-Small Cell Lung Cancer

摘要: 目的：探索蛋白酶体26S亚基非ATP酶2 (Proteasome 26S Subunit, Non.ATPase2, PSMD2)在非小细胞肺癌(Non-small cell lung cancer, NSCLC)患者中的表达特征、预后预测特征及对免疫微环境的影响。方法：基于TCGA数据集中的肺腺癌(Lung adenocarcinoma, LUAD)和肺鳞癌(Lung squamous cell carcinoma, LUSC)相关数据以及GTEx数据集中的健康人相关数据，利用TIMER2.0及GEPIA2在线工具进行基因表达差异分析；利用GEPIA2进行生存分析，并绘制Kaplan-Meier生存曲线，分析PSMD2的预后意义；利用TIMER2.0分析肿瘤组织中免疫细胞浸润情况，采用CIBERSORT算法进行PSMD2表达水平与免疫细胞浸润的相关性预测。结果：PSMD2在LUAD和LUSC组织中高表达，PSMD2表达水平在不同分期NSCLC间具有显著差异(F = 4.59, P < 0.05)，PSMD2表达在LUAD和LUSC中分别进行分期分析时无显著差异。生存分析结果显示，LUAD患者中PSMD2高表达者OS明显短于低表达者(P < 0.05)，DFS无统计学差异，而在LUSC患者中OS及DFS均无统计学意义。免疫浸润分析结果显示，在LUAD中，PSMD2表达水平与Macrophage M0/M1及Neutrophil水平呈正相关，而与B cell memory水平呈负相关；在LUSC中，PSMD2表达水平与Macrophage M0水平呈正相关，而与T cell CD8+，B cell memory以及Neutrophil水平呈负相关。结论：PSMD2在NSCLC中高表达；PSMD2高表达与NSCLC患者差的预后密切相关；PSMD2的表达水平与NSCLC肿瘤免疫相关。

Abstract: Objective: Exploring the gene expression characteristics, prognostic prediction, and impact on the immune microenvironment of PSMD2 (Proteasome 26S Subunit, Non.ATPase2, PSMD2) in non-small cell lung cancer (NSCLC) patients. Methods: Related data of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were based on TCGA data set, and the related data of healthy peo-ple were based on GTEx data set. TIMER2.0 and GEPIA2 online tools were used to mine the expres-sion difference; GEPIA2 was used for survival analysis and drawing Kaplan Meier survival curves to analyze the prognostic significance of PSMD2; TIMER2.0 was used to analyze the infiltration of im-mune cells in tumor tissue, and the CIBERSORT algorithm was used to predict the correlation be-tween PSMD2 expression level and immune cell infiltration. Results: The PSMD2 expression in-creased in LUAD and LUSC tissues, and the expression level of PSMD2 showed significant differences among different stages of NSCLC (F = 4.59, P < 0.05). There is no significant difference in PSMD2 ex-pression during stage analysis in LUAD and LUSC, respectively. The survival analysis results showed that in LUAD patients, those with increased expression of PSMD2 had significantly shorter OS than those with low expression (P < 0.05), and there was no significant difference in DFS. However, in LUSC patients, both OS and DFS were no statistically significant association. The results of immune infiltration analysis showed that in LUAD, the expression level of PSMD2 was positively correlated with Macrophage M0/M1 and Neutrophil levels, while negatively correlated with B cell memory levels; In LUSC, the expression level of PSMD2 is positively correlated with Macrophage M0 level, but negatively correlated with T cell CD8+, B cell memory, and Neutrophil levels. Conclusion: The expression of PSMD2 is increased in NSCLC; The increased expression of PSMD2 is closely related to the poor prognosis of NSCLC patients; The expression level of PSMD2 is associated with tumor im-munity in NSCLC.